Coverart for item
The Resource Envisioning a transformed clinical trials enterprise in the United States : establishing an agenda for 2020, Neil Weisfeld, Rebecca A. English, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies, (electronic resource)

Envisioning a transformed clinical trials enterprise in the United States : establishing an agenda for 2020, Neil Weisfeld, Rebecca A. English, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies, (electronic resource)

Label
Envisioning a transformed clinical trials enterprise in the United States : establishing an agenda for 2020
Title
Envisioning a transformed clinical trials enterprise in the United States
Title remainder
establishing an agenda for 2020
Statement of responsibility
Neil Weisfeld, Rebecca A. English, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies
Contributor
Subject
Language
eng
Summary
  • Recognition is growing that the clinical trials enterprise (CTE) in the United States faces substantial challenges impeding the efficient and effective conduct of clinical research to support the development of new medicines and evaluate existing therapies. A gap has been identified between the desired state where medical care in the United States is provided solely based on high-quality evidence--and the reality--where we have limited ability to generate timely and practical evidence. There have increasingly been calls for transformation of the CTE in the United States to support the efficient development of breakthrough medicines and interventions and the evidence needed for health care decision making. Leaders in research and health care convened to discuss this visionary quest at a 2-day workshop held in November 2011 by the Institute of Medicine (IOM) Forum on Drug Discovery, Development, and Translation. The workshop focused primarily on one type of clinical investigation, randomized controlled trials (RCTs)
  • Recognition is growing that the clinical trials enterprise (CTE) in the United States faces substantial challenges impeding the efficient and effective conduct of clinical research to support the development of new medicines and evaluate existing therapies. A gap has been identified between the desired state where medical care in the United States is provided solely based on high-quality evidence--and the reality--where we have limited ability to generate timely and practical evidence. There have increasingly been calls for transformation of the CTE in the United States to support the efficient development of breakthrough medicines and interventions and the evidence needed for health care decision making. Leaders in research and health care convened to discuss this visionary quest at a 2-day workshop held in November 2011 by the Institute of Medicine (IOM) Forum on Drug Discovery, Development, and Translation. The workshop focused primarily on one type of clinical investigation, randomized controlled trials (RCTs)
  • Recognition is growing that the clinical trials enterprise (CTE) in the United States faces substantial challenges impeding the efficient and effective conduct of clinical research to support the development of new medicines and evaluate existing therapies. A gap has been identified between the desired state where medical care in the United States is provided solely based on high-quality evidence--and the reality--where we have limited ability to generate timely and practical evidence. There have increasingly been calls for transformation of the CTE in the United States to support the efficient development of breakthrough medicines and interventions and the evidence needed for health care decision making. Leaders in research and health care convened to discuss this visionary quest at a 2-day workshop held in November 2011 by the Institute of Medicine (IOM) Forum on Drug Discovery, Development, and Translation. The workshop focused primarily on one type of clinical investigation, randomized controlled trials (RCTs)
  • Recognition is growing that the clinical trials enterprise (CTE) in the United States faces substantial challenges impeding the efficient and effective conduct of clinical research to support the development of new medicines and evaluate existing therapies. A gap has been identified between the desired state where medical care in the United States is provided solely based on high-quality evidence--and the reality--where we have limited ability to generate timely and practical evidence. There have increasingly been calls for transformation of the CTE in the United States to support the efficient development of breakthrough medicines and interventions and the evidence needed for health care decision making. Leaders in research and health care convened to discuss this visionary quest at a 2-day workshop held in November 2011 by the Institute of Medicine (IOM) Forum on Drug Discovery, Development, and Translation. The workshop focused primarily on one type of clinical investigation, randomized controlled trials (RCTs)
  • Recognition is growing that the clinical trials enterprise (CTE) in the United States faces substantial challenges impeding the efficient and effective conduct of clinical research to support the development of new medicines and evaluate existing therapies. A gap has been identified between the desired state where medical care in the United States is provided solely based on high-quality evidence--and the reality--where we have limited ability to generate timely and practical evidence. There have increasingly been calls for transformation of the CTE in the United States to support the efficient development of breakthrough medicines and interventions and the evidence needed for health care decision making. Leaders in research and health care convened to discuss this visionary quest at a 2-day workshop held in November 2011 by the Institute of Medicine (IOM) Forum on Drug Discovery, Development, and Translation. The workshop focused primarily on one type of clinical investigation, randomized controlled trials (RCTs)
Cataloging source
DNLM
Funding information
This study was supported by contracts between the National Academy of Sciences and Department of Health and Human Services (Contract Nos. N01-OD-4-2139 TO #158 and HHSF223001003T), American Society for Microbiology, Amgen Inc., Association of American Medical Colleges, Bristol-Myers Squibb, Burroughs Wellcome Fund, Celtic Therapeutics, LLLP, Critical Path Institute, Doris Duke Charitable Foundation, Eli Lilly & Co., FasterCures, Foundation for the NIH, Friends of Cancer Research, GlaxoSmithKline, Janssen Research & Development, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, and Pfizer Inc.
NLM call number
QV 771.4
http://library.link/vocab/relatedWorkOrContributorName
  • Weisfeld, Neil E
  • English, Rebecca A
  • Claiborne, Anne B
  • Institute of Medicine (U.S.)
http://library.link/vocab/subjectName
  • Clinical Trials as Topic
  • Drug Design
  • Drug Industry
  • Randomized Controlled Trials as Topic
  • United States
Label
Envisioning a transformed clinical trials enterprise in the United States : establishing an agenda for 2020, Neil Weisfeld, Rebecca A. English, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies, (electronic resource)
Instantiates
Publication
Bibliography note
Includes bibliographical references
Contents
  • Introduction -- Integrating community practice and clinical trials -- Improving public participation in clinical trials -- Creating a new business model for clinical trials -- Building an infrastructure to support clinical trials -- Suggesting an agenda for transforming elements of the clinical trials enterprise
  • Introduction -- Integrating community practice and clinical trials -- Improving public participation in clinical trials -- Creating a new business model for clinical trials -- Building an infrastructure to support clinical trials -- Suggesting an agenda for transforming elements of the clinical trials enterprise
  • Introduction -- Integrating community practice and clinical trials -- Improving public participation in clinical trials -- Creating a new business model for clinical trials -- Building an infrastructure to support clinical trials -- Suggesting an agenda for transforming elements of the clinical trials enterprise
Control code
OCM1bookssj0000665821
Dimensions
unknown
Isbn
9780309253154
Specific material designation
remote
System control number
(WaSeSS)bookssj0000665821
Label
Envisioning a transformed clinical trials enterprise in the United States : establishing an agenda for 2020, Neil Weisfeld, Rebecca A. English, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies, (electronic resource)
Publication
Bibliography note
Includes bibliographical references
Contents
  • Introduction -- Integrating community practice and clinical trials -- Improving public participation in clinical trials -- Creating a new business model for clinical trials -- Building an infrastructure to support clinical trials -- Suggesting an agenda for transforming elements of the clinical trials enterprise
  • Introduction -- Integrating community practice and clinical trials -- Improving public participation in clinical trials -- Creating a new business model for clinical trials -- Building an infrastructure to support clinical trials -- Suggesting an agenda for transforming elements of the clinical trials enterprise
  • Introduction -- Integrating community practice and clinical trials -- Improving public participation in clinical trials -- Creating a new business model for clinical trials -- Building an infrastructure to support clinical trials -- Suggesting an agenda for transforming elements of the clinical trials enterprise
Control code
OCM1bookssj0000665821
Dimensions
unknown
Isbn
9780309253154
Specific material designation
remote
System control number
(WaSeSS)bookssj0000665821

Library Locations

    • Thomas Jefferson LibraryBorrow it
      1 University Blvd, St. Louis, MO, 63121, US
      38.710138 -90.311107
Processing Feedback ...